On December 31, 2024, GAGNON SECURITIES LLC (Trades, Portfolio) made a notable addition to its portfolio by acquiring 1,879,496 shares of Profound Medical Corp
The average of price targets set by Wall Street analysts indicates a potential upside of 100.1% in Profound Medical (PROF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
TORONTO, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Profound Medical Corp. (PROF; TSX:PRN) (”Profound” or the ”Company”), a commercial-stage medical device com
BASE SHELF PROSPECTUS IS ACCESSIBLE, AND FINAL PROSPECTUS SUPPLEMENT WILL BE ACCESSIBLE WITHIN TWO BUSINESS DAYS, ON SEDAR+ AND ON EDGAR TORONTO, Dec. 06, 202
”“ Combines Profound's TULSA-PRO® and Siemens Healthineers' Magnetom Free.Max ”“ ”“ Supports the Modern Treatment Pathway that allows for more accurate and
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Feb. 9) Abbott ...
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Feb. 2) Argenx ...
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Jan. 20) 10X ...